NPORT-EX 2 JPMSCGRF.htm 9.30 NPORT PART F EDGAR HTML
JPMorgan Small Cap Growth Fund
Schedule of Portfolio Investments as of September 30, 2023
(Unaudited)
THE “UNAUDITED MUTUAL FUNDS HOLDINGS” LIST (“the
List”) IS TO BE USED FOR REPORTING PURPOSES ONLY.  IT IS
NOT TO BE REPRODUCED FOR USE AS ADVERTISING OR
SALES LITERATURE WITH THE GENERAL PUBLIC. The list is
submitted for the general information of the shareholders of the Fund.
It is not authorized for distribution to prospective investors in the Fund
unless preceded or accompanied by a prospectus. The list has been
created from the books and records of the Fund. Holdings are
available 60 days after the fund’s fiscal quarter, using a trade date
accounting convention, by contacting the appropriate service center.
The list is subject to change without notice. The list is for
informational purposes only and is not intended as an offer or
solicitation with respect to the purchase or sale of any security.
JPMorgan Asset Management is the marketing name for the asset
management business of J.P. Morgan  Chase & Co.
J.P. Morgan Distribution Services, Inc., member FINRA.
© J.P. Morgan Chase & Co., 2023.

JPMorgan Small Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF September 30, 2023  (Unaudited)
INVESTMENTS
SHARES
(000)
VALUE
($000)
Common Stocks — 99.3%
Aerospace & Defense — 1.2%
Hexcel Corp.
667
43,471
Automobile Components — 1.2%
Fox Factory Holding Corp.*
217
21,436
LCI Industries
176
20,700
 
42,136
Automobiles — 0.5%
Winnebago Industries, Inc.(a)
278
16,503
Banks — 0.8%
First Financial Bankshares, Inc.
453
11,395
Pinnacle Financial Partners, Inc.
231
15,472
 
26,867
Biotechnology — 11.2%
ACELYRIN, Inc.* (a)
955
9,716
Agios Pharmaceuticals, Inc.*
715
17,708
Akero Therapeutics, Inc.*
214
10,807
Alector, Inc.*
1,053
6,824
Allogene Therapeutics, Inc.* (a)
1,759
5,576
Amicus Therapeutics, Inc.*
3,833
46,612
Apellis Pharmaceuticals, Inc.* (a)
274
10,430
Arrowhead Pharmaceuticals, Inc.*
943
25,327
Atara Biotherapeutics, Inc.*
2,410
3,568
Blueprint Medicines Corp.*
618
31,023
Coherus Biosciences, Inc.* (a)
2,392
8,944
Halozyme Therapeutics, Inc.*
1,176
44,917
Heron Therapeutics, Inc.* (a)
3,872
3,988
Natera, Inc.*
786
34,767
PMV Pharmaceuticals, Inc.*
1,210
7,428
REGENXBIO, Inc.*
1,149
18,910
Relay Therapeutics, Inc.* (a)
1,330
11,186
REVOLUTION Medicines, Inc.*
1,400
38,754
Sage Therapeutics, Inc.* (a)
619
12,747
Twist Bioscience Corp.*
1,413
28,631
Vaxcyte, Inc.*
157
8,022
Verve Therapeutics, Inc.* (a)
764
10,127
 
396,012
Broadline Retail — 1.0%
Global-e Online Ltd. (Israel)* (a)
901
35,787
Building Products — 3.7%
AAON, Inc.
695
39,491
Advanced Drainage Systems, Inc.
285
32,467
Simpson Manufacturing Co., Inc.
400
59,960
 
131,918

JPMorgan Small Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF September 30, 2023  (Unaudited) (continued)
INVESTMENTS
SHARES
(000)
VALUE
($000)
Common Stocks — continued
Capital Markets — 1.3%
Evercore, Inc., Class A
245
33,777
Hamilton Lane, Inc., Class A
132
11,978
 
45,755
Commercial Services & Supplies — 3.9%
ACV Auctions, Inc., Class A*
2,369
35,970
Casella Waste Systems, Inc., Class A*
639
48,759
MSA Safety, Inc.
335
52,763
 
137,492
Communications Equipment — 0.4%
Ciena Corp.*
321
15,171
Construction & Engineering — 2.4%
EMCOR Group, Inc.
177
37,209
MasTec, Inc.*
257
18,511
Valmont Industries, Inc.
126
30,207
 
85,927
Consumer Staples Distribution & Retail — 2.0%
Chefs' Warehouse, Inc. (The)*
757
16,032
Grocery Outlet Holding Corp.*
1,039
29,969
Performance Food Group Co.*
417
24,564
 
70,565
Diversified Consumer Services — 0.8%
Bright Horizons Family Solutions, Inc.*
340
27,655
Electrical Equipment — 3.2%
Bloom Energy Corp., Class A* (a)
2,197
29,129
NEXTracker, Inc., Class A*
817
32,802
Shoals Technologies Group, Inc., Class A*
1,806
32,959
Vicor Corp.*
294
17,332
 
112,222
Electronic Equipment, Instruments & Components — 0.7%
Littelfuse, Inc.
102
25,156
Energy Equipment & Services — 3.2%
Cactus, Inc., Class A
1,212
60,829
TechnipFMC plc (United Kingdom)
2,641
53,727
 
114,556
Financial Services — 2.1%
Flywire Corp.*
748
23,857
Remitly Global, Inc.*
2,073
52,285
 
76,142
Food Products — 1.1%
Freshpet, Inc.* (a)
598
39,374
Ground Transportation — 0.9%
Saia, Inc.*
81
32,298

JPMorgan Small Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF September 30, 2023  (Unaudited) (continued)
INVESTMENTS
SHARES
(000)
VALUE
($000)
Common Stocks — continued
Health Care Equipment & Supplies — 4.2%
CONMED Corp.
175
17,635
Establishment Labs Holdings, Inc. (Costa Rica)* (a)
318
15,590
Inari Medical, Inc.*
557
36,438
iRhythm Technologies, Inc.*
445
41,969
Outset Medical, Inc.*
1,731
18,831
Shockwave Medical, Inc.*
94
18,758
 
149,221
Health Care Providers & Services — 1.5%
Acadia Healthcare Co., Inc.*
391
27,482
Accolade, Inc.*
2,379
25,174
 
52,656
Health Care Technology — 1.6%
Evolent Health, Inc., Class A*
2,040
55,558
Hotels, Restaurants & Leisure — 5.4%
Boyd Gaming Corp.
688
41,849
Cava Group, Inc.* (a)
218
6,687
Life Time Group Holdings, Inc.* (a)
1,672
25,432
Marriott Vacations Worldwide Corp.
179
18,043
Papa John's International, Inc.(a)
402
27,401
Planet Fitness, Inc., Class A*
361
17,727
Six Flags Entertainment Corp.*
956
22,469
Texas Roadhouse, Inc.
339
32,577
 
192,185
Household Durables — 1.2%
Helen of Troy Ltd.*
152
17,687
Sonos, Inc.*
1,877
24,233
 
41,920
Industrial REITs — 1.0%
Terreno Realty Corp.
644
36,576
IT Services — 1.0%
DigitalOcean Holdings, Inc.* (a)
592
14,230
Globant SA*
100
19,712
 
33,942
Life Sciences Tools & Services — 0.0% ^
Personalis, Inc.*
1,542
1,866
Machinery — 3.3%
Chart Industries, Inc.* (a)
222
37,547
ITT, Inc.
500
48,937
John Bean Technologies Corp.
297
31,213
 
117,697
Oil, Gas & Consumable Fuels — 2.2%
Chord Energy Corp.
100
16,141

JPMorgan Small Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF September 30, 2023  (Unaudited) (continued)
INVESTMENTS
SHARES
(000)
VALUE
($000)
Common Stocks — continued
Oil, Gas & Consumable Fuels — continued
Matador Resources Co.
760
45,213
SM Energy Co.
399
15,842
 
77,196
Personal Care Products — 1.0%
elf Beauty, Inc.*
310
34,047
Pharmaceuticals — 1.9%
Arvinas, Inc.*
691
13,572
Intra-Cellular Therapies, Inc.*
700
36,473
Revance Therapeutics, Inc.*
1,660
19,032
 
69,077
Professional Services — 2.9%
ExlService Holdings, Inc.*
1,155
32,397
KBR, Inc.
923
54,408
Paycor HCM, Inc.* (a)
650
14,835
 
101,640
Semiconductors & Semiconductor Equipment — 4.7%
Allegro MicroSystems, Inc. (Japan)*
729
23,284
Axcelis Technologies, Inc.*
106
17,306
Credo Technology Group Holding Ltd.*
1,478
22,541
MKS Instruments, Inc.
221
19,147
Onto Innovation, Inc.*
127
16,173
Power Integrations, Inc.
288
21,988
Rambus, Inc.*
806
44,962
 
165,401
Software — 13.6%
BlackLine, Inc.*
504
27,963
Box, Inc., Class A*
1,570
38,017
Clear Secure, Inc., Class A(a)
1,028
19,573
Confluent, Inc., Class A*
1,298
38,443
CyberArk Software Ltd.*
314
51,367
Elastic NV*
357
28,960
Envestnet, Inc.*
553
24,359
Everbridge, Inc.*
59
1,316
Five9, Inc.*
453
29,152
Gitlab, Inc., Class A*
268
12,105
HashiCorp, Inc., Class A*
1,323
30,191
JFrog Ltd. (Israel)*
812
20,595
Klaviyo, Inc., Class A* (a)
525
18,109
PowerSchool Holdings, Inc., Class A* (a)
709
16,075
SentinelOne, Inc., Class A* (a)
1,746
29,441
Smartsheet, Inc., Class A*
854
34,566
Vertex, Inc., Class A*
1,351
31,205
Workiva, Inc.*
292
29,618
 
481,055

JPMorgan Small Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF September 30, 2023  (Unaudited) (continued)
INVESTMENTS
SHARES
(000)
VALUE
($000)
Common Stocks — continued
Specialized REITs — 0.6%
CubeSmart
551
21,028
Specialty Retail — 2.6%
Burlington Stores, Inc.*
115
15,607
Floor & Decor Holdings, Inc., Class A* (a)
291
26,330
Lithia Motors, Inc., Class A
130
38,256
Petco Health & Wellness Co., Inc.* (a)
3,116
12,745
 
92,938
Technology Hardware, Storage & Peripherals — 2.4%
Super Micro Computer, Inc.* (a)
307
84,229
Trading Companies & Distributors — 6.6%
Air Lease Corp.
743
29,291
Applied Industrial Technologies, Inc.
502
77,519
FTAI Aviation Ltd.
508
18,057
Rush Enterprises, Inc., Class A
837
34,182
SiteOne Landscape Supply, Inc.*
181
29,624
WESCO International, Inc.
301
43,340
 
232,013
Total Common Stocks
(Cost $3,291,131)
3,515,252
Short-Term Investments — 4.9%
Investment Companies — 0.8%
JPMorgan Prime Money Market Fund Class IM Shares, 5.48%(b) (c)
(Cost $27,797)
27,791
27,799
Investment of Cash Collateral from Securities Loaned — 4.1%
JPMorgan Securities Lending Money Market Fund Agency SL Class Shares, 5.52%(b) (c)
129,012
129,038
JPMorgan U.S. Government Money Market Fund Class IM Shares, 5.27%(b) (c)
16,645
16,645
Total Investment of Cash Collateral from Securities Loaned
(Cost $145,683)
145,683
Total Short-Term Investments
(Cost $173,480)
173,482
Total Investments — 104.2%
(Cost $3,464,611)
3,688,734
Liabilities in Excess of Other Assets — (4.2)%
(148,666
)
NET ASSETS — 100.0%
3,540,068

Percentages indicated are based on net assets.
Abbreviations
 
REIT
Real Estate Investment Trust
^
Amount rounds to less than 0.1% of net assets.
*
Non-income producing security.
 
(a)
The security or a portion of this security is on loan at September 30, 2023. The total value of securities on loan at September 30, 2023 is
$141,948.
 

JPMorgan Small Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF September 30, 2023  (Unaudited) (continued)
(b)
Investment in an affiliated fund, which is registered under the Investment Company Act of 1940, as amended, and is advised by J.P. Morgan
Investment Management Inc.
 
(c)
The rate shown is the current yield as of September 30, 2023.
 

JPMorgan Small Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF September 30, 2023 (Unaudited) (continued)
(Dollar values in thousands)
A. Valuation of Investments  Investments are valued in accordance with U.S. generally accepted accounting principles (“GAAP”) and the Fund's valuation policies set forth by, and under the supervision and responsibility of, the Board of Trustees of the Trust (the “Board”), which established the following approach to valuation, as described more fully below: (i) investments for which market quotations are readily available shall be valued at their market value and (ii) all other investments for which market quotations are not readily available shall be valued at their fair value as determined in good faith by the Board.
Under Section 2(a)(41) of the Investment Company Act of 1940, the Board is required to determine fair value for securities that do not have readily available market quotations. Under SEC Rule 2a-5 (Good Faith Determinations of Fair Value), the Board may designate the performance of these fair valuation determinations to a valuation designee. The Board has designated the Adviser as the “Valuation Designee” to perform fair valuation determinations for the Funds on behalf of the Board subject to appropriate oversight by the Board. The Adviser, as Valuation Designee, leverages the J.P. Morgan Asset Management Americas Valuation Committee (“AVC”) to help oversee and carry out the policies for the valuation of investments held in the Funds. The Adviser, as Valuation Designee, remains responsible for the valuation determinations. 
This oversight by the AVC includes monitoring the appropriateness of fair values based on results of ongoing valuation oversight including, but not limited to, consideration of macro or security specific events, market events, and pricing vendor and broker due diligence. The Administrator is responsible for discussing and assessing the potential impacts to the fair values on an ongoing basis, and, at least on a quarterly basis, with the AVC and the Board.
Equities and other exchange-traded instruments are valued at the last sale price or official market closing price on the primary exchange on which the instrument is traded before the net asset values (“NAV”) of the Fund are calculated on a valuation date.  
Investments in open-end investment companies (“Underlying Funds”) are valued at each Underlying Fund’s net asset values ("NAV") per share as of the report date.
Valuations reflected in this report are as of the report date. As a result, changes in valuation due to market events and/or issuer-related events after the report date and prior to issuance of the report are not reflected herein.
The various inputs that are used in determining the valuation of the Fund's investments are summarized into the three broad levels listed below.
Level 1 Unadjusted inputs using quoted prices in active markets for identical investments.
Level 2 Other significant observable inputs including, but not limited to, quoted prices for similar investments, inputs other than quoted prices that are observable for investments (such as interest rates, prepayment speeds, credit risk, etc.) or other market corroborated inputs.
Level 3 Significant inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Fund's assumptions in determining the fair value of investments).
A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input, both individually and in the aggregate, that is significant to the fair value measurement. The inputs or methodology used for valuing instruments are not necessarily an indication of the risk associated with investing in those instruments. 
The following table represents each valuation input as presented on the Schedule of Portfolio Investments ("SOI"):
 
 
 
 
 
 
Level 1
Quoted prices
Level 2
Other significant
observable inputs
Level 3
Significant
unobservable inputs
Total
Total Investments in Securities(a)
$3,688,734
$
$
$3,688,734

 
(a)
Please refer to the SOI for specifics of portfolio holdings.
B. Investment Transactions with Affiliates  The Fund invested in Underlying Funds advised by the Adviser. An issuer which is under common control with the Fund may be considered an affiliate. The Fund assumes the issuers listed in the table below to be affiliated issuers.

JPMorgan Small Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF September 30, 2023 (Unaudited) (continued)
(Dollar values in thousands)
The Underlying Funds’ distributions may be reinvested into such Underlying Funds. Reinvestment amounts are included in the purchases at cost amounts in the table below.
 
For the period ended September 30, 2023
Security Description
Value at
June 30,
2023
Purchases at
Cost
Proceeds from
Sales
Net Realized
Gain (Loss)
Change in
Unrealized
Appreciation/
(Depreciation)
Value at
September 30,
2023
Shares at
September 30,
2023
Dividend
Income
Capital Gain
Distributions
JPMorgan Prime Money Market Fund
Class IM Shares, 5.48% (a) (b)
$62,312
$227,453
$261,969
$2
$1
$27,799
27,791
$454
$
JPMorgan Securities Lending Money Market
Fund Agency SL Class Shares, 5.52%
(a) (b)
236,014
158,000
265,000
11
13
129,038
129,012
2,675
JPMorgan U.S. Government Money Market
Fund Class IM Shares, 5.27% (a) (b)
50,951
129,443
163,749
16,645
16,645
349
Total
$349,277
$514,896
$690,718
$13
$14
$173,482
$3,478
$

 
(a)
Investment in an affiliated fund, which is registered under the Investment Company Act of 1940, as amended, and is advised by J.P. Morgan
Investment Management Inc.
(b)
The rate shown is the current yield as of September 30, 2023.